Antisense oligonucleotide therapy for triglyceride reduction shows positive top-line results

Akcea Therapeutics and Ionis Pharmaceuticals announced that a phase 2 study of AKCEA-ANGPTL3-LRx for the treatment of patients with hypertriglyceridemia, type 2 diabetes and nonalcoholic fatty liver disease met its primary endpoint of significant triglyceride lowering.
The study also met several secondary endpoints with a favorable tolerability and safety profile, according to a press release from the companies.
AKCEA-ANGPTL3-LRx is an antisense oligonucleotide therapy that reduces production of angiopoietin-like 3 (ANGPTL3) protein in the liver.
The phase 2 study aimed to evaluate the efficacy

Source link

Related posts

Take Home from NASH-TAG: On the precipice of the fatty liver pipeline


Histopathological effects of modern topical sealants on the liver surface after hepatectomy: an experimental swine study


July 2018 Briefing – Gastroenterology


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy